Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only...

por Chong, H., Hutchinson, G., Hart, I. R., Vile, R. G.
Publicado 1998

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

por Harrington, K.J., Vile, R.G., Melcher, A., Chester, J., Pandha, H.S.
Publicado 2010

Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer.

por Alexandroff, A. B., McIntyre, C. A., Porter, J. C., Zeuthen, J., Vile, R. G., Taub, D. D.
Publicado 1998

Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model

por Harrington, K J, Syrigos, K N, Uster, P S, Zetter, A, Lewanski, C R, Gullick, W J, Vile, R G, Stewart, J S W
Publicado 2004

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer

por Mansfield, D C, Kyula, J N, Rosenfelder, N, Chao-Chu, J, Kramer-Marek, G, Khan, A A, Roulstone, V, McLaughlin, M, Melcher, A A, Vile, R G, Pandha, H S, Khoo, V, Harrington, K J
Publicado 2016